• In the media
  • Improving data sharing to increase the effici...
Media - published on 23 Oct 2020

Improving data sharing to increase the efficiency of antibiotic R&D

The authors of this commentary highlight how sharing data can reduce redundancies and accelerate antibacterial R&D, citing the AMR Benchmark as "a good example of how one organisation leveraged its platform to help foster more data sharing".

The commentary summarises the threat from AMR and how it is exacerbated by the trend of big pharmaceutical companies leaving the antibiotic market, leaving smaller biotech companies shouldering the burden of antibiotic R&D. There are steps being made to address this market failure, but change is likely to take time. In the meantime, to increase the chance of scientific success for the companies that remain engaged, the authors set out the case for broader data sharing, even by companies that have now left the field.

"Such data sharing is critical to advancing antibiotic discovery efforts, because when projects are discontinued or programmes fail, treasure troves of data may be shelved, locked away or, in some cases, gone forever. Ensuring data are made available in a timely manner, regardless of whether a project continues or concludes, could make a big difference for this resource-strapped field by eliminating unnecessary and wasteful redundancy in the deployment of limited funds."

Authors: Wes KimKevin KrauseZak Zimmerman & Kevin Outterson



Got a question?

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.

Back to top |